AJP Asia Intelligence Agency

Soulsoft Wins Innovation Award for AI Weight Scale Managing Metabolic Disorders

Soulsoft, awarded the InnoBiz Association Chairman's Award at the 2026 K-Global Innovation Awards, is a healthcare company that developed the 'Jeda' platform, which connects body composition measurement, metabolic disease risk prediction, and personalized health management. The company combines an AI-enabled scale with a health management app to help users manage chronic disease risks in their daily lives.


The flagship product, 'Jeda Body X8', measures 56 body composition items using an 8-electrode dual-frequency method. It applies AI to predict the risk of metabolic syndrome using body composition data without blood tests. According to Soulsoft, the accuracy of body fat measurement is 98.9% compared to DEXA, a hospital-grade device. The performance of the metabolic syndrome prediction AI recorded an AUC of 0.90 in tests certified by the Korea Telecommunications Technology Association (TTA), utilizing data from 25,000 patients at Keimyung University Dongsan Medical Center.


The measurement results are linked to diet and exercise recommendations in the 'Jeda' app. The app analyzes meal photos to provide nutritional information and supports generative AI coaching. By developing both the scale and app in-house, the product price has been lowered to 169,000 won (KRW).


The market response has been positive. After launching the product through crowdfunding, 406 units were sold within seven weeks, achieving a funding success rate of 4,627%. This places it fifth in real-time achievement rates in the tech and electronics sector. The app retention rate is approximately 50%, with a purchase satisfaction score of 5.0.


Recently, the company has been expanding its collaboration in public health projects. It has supplied products to health initiatives in five districts of Gwangju and is conducting joint clinical research with medical institutions. In the United States, it is pursuing sales through Medicare-linked insurance companies and is in discussions for local sales in Taiwan, Singapore, India, and Vietnam. Soulsoft is also seeking approval for software as a medical device (SaMD) to broaden its entry into the public healthcare market.





* This article has been translated by AI.